The object of the study was to evaluate the therapeutic effectiveness and tolerability of miocamycin, a new macrolide antibiotic, in 86 patients with lower respiratory tract infections. The mean peak concentration of miocamycin was determined in bronchial secretions. High concentrations were recorded, in some cases exceeding serum levels. The pathogens were eradicated in all cases, with few side-effects.